Biotech Co.* | Pharma Co. (Country) | Product | Terms/Details (Date) |
| | |||
Alpha Innotech | Panomics Inc. | FluorChem fluorescence and chemiluminescence imaging system and the TranSignal chemiluminescense- based membrane array products | Strategic alliance to jointly market their respective products (2/25) |
Atrix Laboratories | Luxembourg Pharmaceuticals | Eligard leuprolide acetate prostate cancer products | Exclusive licensing agreement for the Israeli marketing rights to Atrix's four Eligard leuprolide acetate prostate cancer products; Atrix will get a royalty on net sales; Luxembourg will be responsible for regulatory submissions and any studies necessary to gain approval in Israel; Atrix will manufacture the products (3/8) |
BioHeart | Cambrex Corp. | MyoCell therapy | Supply agreement in which Cambrex will contract manufacture BioHeart's autologous MyoCell therapy; Cambrex will support BioHeart's worldwide trials (3/12) |
Genzyme Transgenics Corp. (GZTC) | Fresenius AG (Germany) | Recombinant human serum albumin (rhSA) | Fresenius gained rights to market rhSA in Japan; it paid $1.2M for the rights; it already had rights in Europe, North America and the rest of Asia (4/8) |
IDEC Pharma- | Syncor International Corp. | Zevalin (ibritumomab tiuxetan | Syncor will prepare and distribute patient-specific doses of Zevalin (2/28) |
Ligand Pharma- | Royalty Pharma AG (Switzerland) | Three late-stage selective estrogen receptor modulator products | Ligand was paid $6M in exchange for a right to receive 0.25% of net sales of the products for a period of 10 years; Royalty has options to purchase at escalating prices additional rights to receive up to 1% of the products' net sales for a period of 10 years, for a total of $56M (3/7) |
NextGen Sciences Ltd. (UK)* | PerkinElmer | ProteinArray Workstation | PerkinElmer Life Sciences will manufacture and have exclusive worldwide distribution rights to the system (3/12) |
Sanguine Corp.* | Ascendiant-South America LLC (affiliate of Ascendiant Capital Group Inc.) | PHER-02 | Agreement is for Ascendiant to begin manufacturing and distribution of PHER-02 in major countries in South America; PHER-02 is an oxygen-carrying synthetic substitute for human red blood cells (4/3) |
Senetek plc | Enprani Co. Ltd. (Korea) | Kinetin | Agreement for Enprani to market and distribute Kinetin in South Korea; the licensing agreement calls for an undisclosed up-front royalty payment to Senetek, guaranteed annual minimum sales and royalties on future products sold; the companies will collaborate on the manufacture of the Kinetin products (4/16) |
Viragen Inc. | AGC (Pakistan) and Metdem Healthcare Ltd. (Turkey) | Natural alpha interferon, Multiferon | Viragen has two agreements with international drug distributors for its natural alpha interferon, Multiferon; AGC will distribute it in the Middle East and Metdem Healthcare will distribute it in Turkey; deal is worth $22M (4/3) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; NYSE = New York Stock Exchange | |||
